A biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, disorders, with an initial focus on obesity.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
I believe this "contrave" will be extremely critical coming Jan 31 when FDA approves or disapprove. The Board of Review already voted 13-7 most of the time the FDA approves on the recommendations. The other two Arena and VVUS pose no threat here but VVUS already gone over seas to seek aprroval but if Contrave Approves most likely they will try to go ove to Europe to Broaden sales and groth to the company. All in all its in the Bag!